BMY - Calithera Terminating Partnership And Other News: The Good Bad And Ugly Of Biopharma
Calithera signals terminating partnership with Incyte
Calithera Biosciences Inc. (CALA) reported that it has sent a written intimation to Incyte (INCY) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entered into a collaboration in January 2017. The deal mainly pertained to the development and commercialization of first-in-class, small molecule arginase inhibitor, CB-1158 for various indications, including cancer and hematology.
Calithera stated that the dissolution of the collaboration will entail Incyte bearing all development costs for INCB001158 or any other licensed products. Incyte